Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors
The management of the residual mass in the retroperitoneum following induction chemotherapy for metastatic testicular cancer has evolved over the past three decades. A multidisciplinary approach involving cisplatin-based chemotherapy and postchemotherapy retroperitoneal lymph node dissection (PC-RPL...
Main Authors: | Hugh J. Lavery, Robert R. Bahnson, David S. Sharp, Kamal S. Pohar |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2009-10-01
|
Series: | Therapeutic Advances in Urology |
Online Access: | https://doi.org/10.1177/1756287209350315 |
Similar Items
-
Predictors of viable germ cell tumor in postchemotherapeutic residual retroperitoneal masses
by: Khalid Al Othman, et al.
Published: (2014-01-01) -
Is the percentage of teratoma in the orchiectomy specimen predictive of teratoma in retroperitoneal residual masses after chemotherapy in nonseminomatous germ cell tumors?
by: H. Boussaffa, et al.
Published: (2020-11-01) -
Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis
by: John P Fitzgerald, et al.
Published: (2010-01-01) -
Management of residual mass in nonseminomatous germ cell tumors following chemotherapy
by: Siamak Daneshmand, et al.
Published: (2011-08-01) -
Laparotomy for post chemotherapy residue in ovarian germ cell tumors
by: Mathew G, et al.
Published: (2006-01-01)